Clinical Trials Sponsored by Nexstar Pharmaceuticals

Total 19995 results

Overseas Pharmaceuticals, Ltd.
Beijing Capton Pharmaceutical Technology Development Co., LTD

Not yet recruiting

An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Two-way Crossover, Oralcomparative Pharmacokinetic（PK）Study of Lacosamide Extended-Release Tablets , Adult, Human Subjects Under Fasting Conditions.

Epilepsy

China
Overseas Pharmaceuticals, Ltd.
Guangzhou Health Start Pharmaceutical Techology Co.,Ltd

Not yet recruiting

An Comparative Pharmacokinetic Study of Amlodipine Besylate Controlled-release Tablets,China in Normal, Healthy, Adult, Human Subjects Under Fasting Conditions

Hypertension

China
Tasly GeneNet Pharmaceuticals Co., Ltd

Recruiting

A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

Charcot-Marie-Tooth Type 1A

China
Tetraphase Pharmaceuticals, Inc.
PRA Health Sciences

Completed

Phase 1, Safety and Bronchopulmonary PK Study in Healthy Volunteers (BAL)

Healthy Subjects

United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.
Cephalon; ChemGenex Pharmaceuticals

Completed

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

Chronic Myeloid Leukemia

United States, Canada, France, Germany, Hungary, India, Italy, Poland, Singapore, United Kingdom
Auspex Pharmaceuticals, Inc.

Completed

Alternatives for Reducing Chorea in Huntington Disease (ARC-HD)

Chorea Associated With Huntington Disease

United States, Australia, Canada
Teva Pharmaceuticals USA
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

Osteoporosis, Postmenopausal

United States, Bulgaria, Czechia, Georgia, Germany, Hungary, Poland, Russian Federation, Slovakia, Ukraine
Auspex Pharmaceuticals, Inc.

Completed

Reducing Involuntary Movements in Participants With Tardive Dyskinesia (RIM-TD)

Tardive Dyskinesia

United States, Czechia, Germany, Hungary, Poland, Slovakia
Auspex Pharmaceuticals, Inc.

Completed

A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)

TOURETTE SYNDROME

United States
Auspex Pharmaceuticals, Inc.

Completed

Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD)

Tardive Dyskinesia

United States, Czechia, Germany, Hungary, Poland, Slovakia
Telix Pharmaceuticals (Innovations) Pty Limited
Grand Pharmaceutical (China) Co., Ltd.

Recruiting

68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Prostate Cancer | Biochemical Recurrence of Malignant Neoplasm of Prostate | BCR Prostate Carcinoma

China
Teva Branded Pharmaceutical Products R&D, Inc.
Cephalon; ChemGenex Pharmaceuticals

Completed

Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

Chronic Myeloid Leukemia

United States, Canada, France, Germany, Hungary, India, Italy, Poland, Singapore, United Kingdom
Auspex Pharmaceuticals, Inc.

Completed

Aim to Reduce Movements in Tardive Dyskinesia (ARM-TD)

Tardive Dyskinesia

United States, Poland, Czechia, Slovakia
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma

China, Belgium, Thailand, United States, Spain, Canada, Colombia, Italy, Morocco, Brazil, Turkey, Chile, Malaysia, Israel, Portugal, Singapore, Russian Federation, Philippines, Tunisia, Austria, Czechia, Germany, Hungary, India, Poland, R... and more
Teva Pharmaceuticals Europe

Completed

Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease (SPRINT)

Chronic Obstructive Pulmonary Disease | Asthma

Croatia, Denmark, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom
Medstar Health Research Institute
Genentech, Inc.

Terminated

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

HER-2 Positive Metastatic Breast Cancer

United States
Medstar Health Research Institute
Genentech, Inc.

Completed

Cardiac Safety Study in Patients With HER2 + Breast Cancer (SAFE-HEaRt)

Left Ventricular Function Systolic Dysfunction | HER2 Positive Breast Cancer

United States
Cynthia West

Completed

Stop Atherosclerosis in Native Diabetics Study (SANDS)

Hypertension | Cardiovascular Disease | Diabetes | Carotid Atherosclerosis | Hyperlipidemia

United States
Medstar Health Research Institute
Georgetown University

Withdrawn

The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma

Hypothyroidism | Thyroid Carcinoma

United States
Medstar Health Research Institute
Cardinal Health

Completed

The Safety and Efficacy of an Extravascular, Water-Soluble Sealant for Venous Access-Site Closure

Cardiac Diagnostic Procedure | Cardiac Interventional Procedure | Femoral Access Site Closure

United States
Rebecca Torguson

Completed

Registry Experience at the Washington Hospital Center, DES - Xience V (REWARDS XV)

Coronary Artery Disease

United States
Biotronik AG
Medstar Health Research Institute

Unknown

BIOVALVE - I / II Clincial Investigation (BIOVALVE)

Aortic Valve Stenosis | Heart Valve Diseases

Belgium, Germany, Switzerland, Netherlands
Georgetown University
Medstar Health Research Institute

Withdrawn

Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

Gestational Diabetes

United States
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Melanoma

Canada, Australia, France, Italy, Brazil, United States, Argentina, Austria, Belgium, Chile, Czechia, Finland, Germany, Greece, Ireland, Israel, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Spain, Sweden and more
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, France, Australia, Italy, Greece, Israel, Russian Federation, New Zealand, Austria, United Kingdom, Netherlands, Portugal, Poland, Czechia, Romania
Medstar Health Research Institute
Latham Fund

Recruiting

Treatment of Hypopigmented Scars With Bimatoprost

Burn Scar | Cicatrix | Scars | Cicatrix, Hypertrophic | Pigmentation Disorder | Scarring | Hypopigmented Skin | Hypopigmented Scar | Burns Laser

United States
SonoMedica, Inc.
Medstar Health Research Institute

Terminated

Evaluation of the CardioSond Electronic Stethoscope in the Detection of Coronary Artery Disease

Coronary Artery Disease

United States
Georgetown University
Medstar Health Research Institute

Completed

Using Transcranial Direct Current Stimulation (tDCS) to Improve Post-Stroke Aphasia

Aphasia

United States
Medstar Health Research Institute
Sequenom Laboratories

Completed

The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage

Miscarriage | Intrauterine Fetal Demise | Circulating Cell Free Fetal DNA

United States
Georgetown University
Medstar Health Research Institute

Completed

Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Adults on Antibiotics (PHASE)

Adults on Antibiotics

United States
ISA Pharmaceuticals
Regeneron Pharmaceuticals

Active, not recruiting

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Squamous Cell Carcinoma of the Oropharynx | HPV16 Positive

Netherlands, United States, United Kingdom, France, Belgium, Czechia, Spain, Italy, Germany, Brazil, Hungary, Mexico, Poland
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)

Healthy Volunteers
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)

Healthy Volunteers
Portola Pharmaceuticals

Completed

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Hepatic Impairment

United States
Portola Pharmaceuticals

Withdrawn

BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes

Venous Thromboses

United States
Jazz Pharmaceuticals
GW Pharmaceuticals

Completed

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Seizures | Tuberous Sclerosis Complex

United States
Solvay Pharmaceuticals
Unimed Pharmaceuticals

Completed

Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism

Primary or Secondary Hypogonadism | Constitutional Delay in Growth and Puberty (CDGP)

United States
Solvay Pharmaceuticals
Unimed Pharmaceuticals

Completed

Pharmacokinetic Evaluation of Testosterone Gel (1%)

Primary or Secondary Hypogonadism | Constitutional Delay in Growth and Puberty (CDGP)

United States
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread (PIVOT IO 011)

Renal Cell Carcinoma

United States, Argentina, Brazil, Canada, France, Germany, Mexico, Russian Federation
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma

United States, Argentina, Brazil, Australia, Singapore, New Zealand, Russian Federation, Mexico, Peru, Chile
Stony Brook University
Nektar Therapeutics

Completed

Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanical Ventilation

Ventilator Associated Pneumonia | Respiratory Infection | Tracheobronchitis

United States
Medstar Health Research Institute
Media Rez

Recruiting

mHealth for Breast Cancer Survivors With Insomnia

Insomnia | Breast Cancer Survivor

United States
Medstar Health Research Institute
Medtronic Cardiovascular

Active, not recruiting

CoreValve Evolut Pro Prospective Registry

Aortic Stenosis

United States
Rebecca Torguson

Completed

Registry Experience at the Washington Hospital Center, DES - Endeavor for Myocardial Infarction (REWARDS-EMI)

Coronary Artery Disease

United States
Darma Inc.
Medstar Health Research Institute

Completed

Pilot Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients Patients

Vital Sign Monitoring

United States
VeraLight, Inc.
Medstar Health Research Institute

Completed

Using SCOUT Noninvasive AGE Measurements to Forecast Diabetes Complications (MARC)

Type 1 Diabetes | Type 2 Diabetes

United States
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bladder Cancer | Bladder Tumor | Muscle-Invasive Bladder Cancer

Russian Federation, China, Germany, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Greece, Israel, Mexico, Netherlands, Poland, Spain, United Kingdom
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10)

Neoplasm Metastasis | Urinary Bladder Neoplasm

United States, Spain, United Kingdom, Belgium, Canada, Australia, France, Italy, Greece, Germany, Portugal, Argentina, Israel, Russian Federation, Turkey, Mexico, Finland, Netherlands
Bristol-Myers Squibb
Nektar Therapeutics

Terminated

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (PIVOT IO 020)

Ewing Sarcoma | Ependymoma | Medulloblastoma | Neuroblastoma | Rhabdomyosarcoma | High-grade Glioma | Leukemia and Lymphoma | Miscellaneous Brain Tumors | Miscellaneous Solid Tumors | Relapsed, Refractory Malignant Neoplasms

United States, Australia, France, Germany, Italy, Spain
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (PIVOT-02)

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Urothelial Carcinoma | HR+/HER2- Breast Cancer

United States, Spain, Canada, France, Italy, Belgium, Poland, United Kingdom

Clinical Trials Sponsored by Nexstar Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations